Unite Life Sciences is thrilled to confirm Marvella E. Ford, PhD, Associate Director, Population Sciences and Cancer Disparities Hollings Cancer Center; Melissa Gonzales, Inclusion Principal, External Partnering, Genentech, and Dr. Kevin Knopf MD, Division Chief Hematology/Oncology, Highland Hospital/ Alameda Health System for the 2021 Clinical Trial Diversity Strategies Advisory Board. 

In October, they joined us along with Lola Fashoyin-Aje of the FDA, to discuss how disparate rates of enrollment of racial and ethnic minorities and medically underserved populations in cancer clinical trials impacts the validity of trial results and increases health disparities for under-served communities and patients. Ahead of our February Clinical Trial Diversity Strategies online event, view their dynamic session and explore how trials might engage novel strategies to diversify their studies and also the wider social and economic factors affecting health equity that need to be addressed to truly overcome barriers for cancer patients from underrepresented populations.